GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (MEX:GSK N) » Definitions » Cyclically Adjusted Revenue per Share

GSK (MEX:GSK N) Cyclically Adjusted Revenue per Share : MXN483.72 (As of Mar. 2025)


View and export this data going back to 2003. Start your Free Trial

What is GSK Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Mar. 2025 was MXN96.041. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN483.72 for the trailing ten years ended in Mar. 2025.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 9.10% per year. The lowest was 0.60% per year. And the median was 4.50% per year.

As of today (2025-06-27), GSK's current stock price is MXN791.00. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN483.72. GSK's Cyclically Adjusted PS Ratio of today is 1.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.50. The lowest was 1.48. And the median was 2.01.


GSK Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 501.49 539.29 387.39 363.47 418.53

GSK Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 350.47 386.17 425.11 418.53 483.72

Competitive Comparison of GSK's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.


;
;

GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=96.041/136.1000*136.1000
=96.041

Current CPI (Mar. 2025) = 136.1000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 73.810 100.100 100.355
201509 81.400 100.200 110.564
201512 82.003 100.400 111.161
201603 78.090 100.400 105.857
201606 88.285 101.000 118.966
201609 97.729 101.500 131.044
201612 98.475 102.200 131.139
201703 87.254 102.700 115.631
201706 86.668 103.500 113.966
201709 96.140 104.300 125.452
201712 101.140 105.000 131.097
201803 92.644 105.100 119.970
201806 96.255 105.900 123.704
201809 99.486 106.600 127.017
201812 102.152 107.100 129.812
201903 98.330 107.000 125.072
201906 95.230 107.900 120.119
201909 114.492 108.400 143.749
201912 108.658 108.500 136.298
202003 131.632 108.600 164.964
202006 109.620 108.800 137.126
202009 122.722 109.200 152.953
202012 -13.321 109.400 -16.572
202103 104.381 109.700 129.501
202106 80.728 111.400 98.627
202109 92.342 112.400 111.813
202112 95.064 114.700 112.800
202203 92.778 116.500 108.387
202206 67.587 120.500 76.337
202209 87.254 122.300 97.100
202212 85.651 125.300 93.034
202303 74.445 126.800 79.905
202306 75.923 129.400 79.854
202309 85.425 130.100 89.365
202312 83.985 130.500 87.589
202403 75.503 131.600 78.085
202406 89.161 133.000 91.239
202409 100.785 133.500 102.748
202412 102.966 135.100 103.728
202503 96.041 136.100 96.041

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GSK  (MEX:GSK N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=791.00/483.72
=1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.50. The lowest was 1.48. And the median was 2.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (MEX:GSK N) » Definitions » Cyclically Adjusted Revenue per Share
Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK Headlines

No Headlines